Abstract: The present disclosure provides a Paenibacillus strain, and a hemostatic polysaccharide produced by same and use thereof. In the present disclosure, a Paenibacillus sp. 1229 has a deposit number of CCTCC NO: M 2022553. A produced exopolysaccharide (EPS) Hemoadhican has a hemostatic function, and can be prepared as a hemostatic material in different dosage forms for different types of hemostasis. The hemostatic material has a high hemostatic speed, no need for applying pressures to the wound for a long time, safety and non-toxicity, desirable biocompatibility, and no requirement of removal after use. The material is suitable for the application of hemostasis in irregular bleeding such as solid organs in vitro or in vivo and diffuse bleeding.

Abstract: Oligosaccharide riclinoctaose is used in preparation of a drug for treating and/or preventing ischemia-reperfusion injury (IRI). The oligosaccharide riclinoctaose has a structural formula as follows: The oligosaccharide riclinoctaose can significantly relieve postoperative liver injury, kidney injury, and brain injury in ischemia-reperfusion mice.